comparemela.com

Page 11 - Peter Emery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Electricity North West: East Lancashire views sought on £2 billion investment

EAST LANCASHIRE residents are being asked to give their views on an planned £2 billion investment in the region s electricity network. Electricity North West has already set out its draft plan on how intends to spend the money supporting the region s green future and has spoken to over 18,000 people. However, before the plans are submitted to energy regulator Ofgem, the company hopes that its customers can have their say once again through an online questionnaire. Electricity North West chief executive Peter Emery said: “The challenge of delivering stretching environmental ambitions on net zero while keeping bills low and making sure we don’t leave anybody behind is tough.

Electricity North West: East Lancashire views sought on £2 billion investment

Electricity North West: East Lancashire views sought on £2 billion investment
thelancasterandmorecambecitizen.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancasterandmorecambecitizen.co.uk Daily Mail and Mail on Sunday newspapers.

Electricity North West unveils big investment plans for the north west and Cumbria

Electricity North West unveils big investment plans for the north west and Cumbria

Electricity North West unveils big investment plans for the north west and Cumbria
nwemail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nwemail.co.uk Daily Mail and Mail on Sunday newspapers.

Rescue plan for failed biotech company

Rescue plan for failed biotech company A recapitalization plan for failed Queensland biotech Medigard has emerged a year after COVID-19 torpedoed the ASX-listed company’s fundraising efforts. Business by Glen Norris Premium Content Subscriber only A recapitalization plan for failed Queensland biotech Medigard has emerged a year after COVID-19 torpedoed the ASX-listed company s fundraising efforts. The Gold Coast-based company, which listed on the stock exchange in 2004, had developed a retractable syringe that was licensed to a Chinese manufacturer. But while the syringe experienced some success in international markets, sales were well below expectations. In the three years prior to its collapse, the company had been exploring new medical injectable developments including a treatment for degenerative disc disease.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.